Programmed Cell Death Ligand 1 Expression in Osteosarcoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer immunology research

• Publication date

  2014-04-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-13-0224PMID 24866169PMCID PMC4082476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Programmed death ligand-1 expression in non-small cell lung cancer

  2014influential reference
• Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

  2013cited by this paper
• A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

  2013cited by this paper
• Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma

  2013cited by this paper
• WHO classification of tumours of soft tissue and bone

  2013cited by this paper
• Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80

  2011cited by this paper
• PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

  2011cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Novel therapeutic agents for osteosarcoma

  2009cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• Osteosarcoma incidence and survival rates from 1973 to 2004

  2009cited by this paper
• Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients

  2009cited by this paper
• The epidemiology of osteosarcoma.

  2009cited by this paper
• Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients.

  2009cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

  2008cited by this paper
• Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

  2007cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Management of osteosarcoma

  2006cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Biology and therapeutic advances for pediatric osteosarcoma.

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy

  2003cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

  2003cited by this paper
• B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

  1998influential reference
• Osteosarcoma.

  1997cited by this paper

• Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.

  2026cites this paper
• Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy

  2026cites this paper
• Antitumor Effects of PD-1 Blockade Combined with Mild Hyperthermia in a Murine Osteosarcoma Model.

  2026cites this paper
• Signature of immune infiltration-related ferroptosis genes to predict the prognosis of patients with osteosarcoma

  2025cites this paper
• Risk score model with two immune infiltration-related long non-coding RNAs to predict prognosis in patients with osteosarcoma

  2025cites this paper
• Chimeric PD-1 receptor redirects primary T cells against childhood solid tumors but not to PD-1 ligand-positive CD80-coexpressing cells

  2025cites this paper
• Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives

  2025cites this paper
• Decoding the role of SLC25A5 in osteosarcoma drug resistance and CD8+ T cell exhaustion: The therapeutic potential of phyllanthin.

  2024cites this paper
• Modulating tumor-associated macrophage polarization by anti-maRCO mAb exerts anti-osteosarcoma effects through regulating osteosarcoma cell proliferation, migration and apoptosis

  2024cites this paper
• Biomaterials‐Boosted Immunotherapy for Osteosarcoma

  2024cites this paper
• PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs

  2024cites this paper
• Primary osteosarcoma of the breast during lactation: a case report and literature review

  2024cites this paper
• Promise and Challenges of T Cell Immunotherapy for Osteosarcoma

  2023influential citation
• [Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer].

  2023cites this paper
• Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

  2023cites this paper
• Immunotherapeutic Strategies in the Management of Osteosarcoma

  2023cites this paper
• Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

  2023cites this paper
• PROGNOSTIC IMPLICATIONS OF PD-L1 EXPRESSION AND LOSS OF PTEN IN PATIENTS WITH RHABDOMYOSARCOMA, EWING'S SARCOMA AND OSTEOSARCOMA.

  2023cites this paper
• Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients

  2023cites this paper
• Oral TGF-βR1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

  2023cites this paper
• Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

  2023cites this paper
• Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy

  2023cites this paper
• Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma

  2022cites this paper
• First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001.

  2022cites this paper
• The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes

  2022cites this paper
• Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality

  2022cites this paper
• PD-L1, a Potential Immunomodulator Linking Immunology and Orthodontically Induced Inflammatory Root Resorption (OIIRR): Friend or Foe?

  2022cites this paper
• ICSBP-induced PD-L1 enhances osteosarcoma cell growth

  2022cites this paper
• Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1α under Hypoxia

  2022cites this paper
• Origin and Therapies of Osteosarcoma

  2022cites this paper
• Immunorthodontics: Role of HIF-1α in the Regulation of (Peptidoglycan-Induced) PD-L1 Expression in Cementoblasts under Compressive Force

  2022cites this paper
• Discovery of novel sulphonamide hybrids that inhibit LSD1 against bladder cancer cells

  2022cites this paper
• Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury

  2022cites this paper
• Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma

  2022cites this paper
• Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma

  2022cites this paper
• Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy

  2021cites this paper
• Thrombospondin‐1 induced programmed death‐ligand 1‐mediated immunosuppression by activating the STAT3 pathway in osteosarcoma

  2021cites this paper
• Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma

  2021cites this paper
• The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

  2021cites this paper
• MicroRNA‐519d‐3p antagonizes osteosarcoma resistance against cisplatin by targeting PD‐L1

  2021cites this paper
• High Expression of TIM 3 and Galectin 9 on Immunohistochemistry Staining of Tumor Specimen at Diagnosis in Pediatric Patients with Ewing Sarcoma

  2021cites this paper
• T cell exhaustion drives osteosarcoma pathogenesis

  2021cites this paper
• BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma

  2021cites this paper
• Correlation between vascular endothelial growth factor (VEGF) expression with histopathological findings in osteosarcoma

  2021cites this paper
• Olaratumab’s failure in soft tissue sarcoma

  2021cites this paper
• The PD‐1/PD‐L1 binding inhibitor BMS‐202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway

  2021cites this paper
• The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response

  2021cites this paper
• Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

  2021cites this paper
• Targeted Therapies and Checkpoint Inhibitors in Sarcoma.

  2021cites this paper
• Classification of Osteosarcoma Based on Immunogenomic Profiling

  2021cites this paper
• Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma

  2021cites this paper
• Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force

  2021cites this paper
• Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes

  2021cites this paper
• Effect of PD鄄L1 on the proliferation,invasion and migration of hepatocellular carcinoma cells

  2020cites this paper
• Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5

  2020cites this paper
• PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions

  2020cites this paper
• Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation

  2020cites this paper
• Sarcomas - a barren immunological wasteland or field of opportunity for immunotherapy?

  2020cites this paper
• LINC00657 activates PD‐L1 to promote osteosarcoma metastasis via miR‐106a

  2020influential citation
• IDO Targeting in Sarcoma: Biological and Clinical Implications

  2020cites this paper
• MAPK7 variants related to prognosis and chemotherapy response in osteosarcoma.

  2020cites this paper
• Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5

  2020cites this paper
• The immune microenvironment of uterine adenosarcomas

  2020cites this paper
• Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma

  2020cites this paper
• Current Perspectives, Challenges and Advances in Cell Based Therapies

  2020cites this paper
• Inhibition of immunity control points in ovarian cancer

  2020cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020influential citation
• Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.

  2020cites this paper
• Development of an immune-related prognostic index associated with osteosarcoma

  2020cites this paper
• Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.

  2020cites this paper
• Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis

  2020cites this paper
• Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.

  2020cites this paper
• Targeting centrosome amplification in aneuploid B-cell precursor acute lymphoblastic leukemia

  2020cites this paper
• LRP8 activates STAT3 to induce PD-L1 expression in osteosarcoma

  2020cites this paper
• Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability

  2020cites this paper
• Comparative Immunology and Immunotherapy of Canine Osteosarcoma.

  2020cites this paper
• Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.

  2020cites this paper
• Genomics and the Immune Landscape of Osteosarcoma.

  2020cites this paper
• Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

  2020cites this paper
• Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy

  2020cites this paper
• Identification of Immune-Related Prognostic Genes and LncRNAs Biomarkers Associated With Osteosarcoma Microenvironment

  2020cites this paper
• A Review of T-Cell Related Therapy for Osteosarcoma

  2020cites this paper
• The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.

  2020cites this paper
• Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients

  2020cites this paper
• Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer

  2019cites this paper
• Ovarian carcinosarcoma: Current developments and future perspectives.

  2019cites this paper
• Current and Emerging Targets in Immunotherapy for Osteosarcoma

  2019cites this paper
• Advances in immune checkpoint inhibitors for bone sarcoma therapy

  2019cites this paper
• PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway

  2019cites this paper
• Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM‐JAK‐PD‐L1 pathway

  2019cites this paper
• Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy

  2019cites this paper
• Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways

  2019cites this paper
• The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma

  2019cites this paper
• Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma

  2019cites this paper
• TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas

  2019cites this paper
• High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

  2019cites this paper
• Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma

  2019cites this paper
• Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas

  2019cites this paper
• Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway

  2019cites this paper
• Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

  2019cites this paper